Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic Chondrocytes

Gerben M. van Buul,* ‡ MD, Wendy L.M. Koevoet,‡ BSc, Nicole Kops,* BSc, P. Koen Bos,* MD, PhD, Jan A.N. Verhaar,‡ MD, PhD, Harrie Weinans,* PhD, Monique R. Bernsen,‡ PhD, and Gerjo J.V.M. van Osch,* ‡ § PhD

Investigation performed at Erasmus MC, Rotterdam, the Netherlands

Background: Platelet-rich plasma (PRP) has recently been postulated as a treatment for osteoarthritis (OA). Although anabolic effects of PRP on chondrocytes are well documented, no reports are known addressing effects on cartilage degeneration. Since OA is characterized by a catabolic and inflammatory joint environment, the authors investigated whether PRP was able to counteract the effects of such an environment on human osteoarthritic chondrocytes.

Hypothesis: Platelet-rich plasma inhibits inflammatory effects of interleukin-1 (IL-1) beta on human osteoarthritic chondrocytes.

Study Design: Controlled laboratory study.

Methods: Human osteoarthritic chondrocytes were cultured in the presence of IL-1 beta to mimic an osteoarthritic environment. Medium was supplemented with 0%, 1%, or 10% PRP releasate (PRPr, the active releasate of PRP). After 48 hours, gene expression of collagen type II alpha 1 (COL2A1), aggrecan (ACAN), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)4, ADAMTS5, matrix metalloproteinase (MMP)13, and prostaglandin-endoperoxide synthase (PTGS)2 was analyzed. Additionally, glycosaminoglycan (GAG) content, nitric oxide (NO) production, and nuclear factor kappa B (NFκB) activation were studied.

Results: Platelet-rich plasma releasate diminished IL-1 beta–induced inhibition of COL2A1 and ACAN gene expression. The PRPr also reduced IL-1 beta–induced increase of ADAMTS4 and PTGS2 gene expression. ADAMTS5 gene expression and GAG content were not influenced by IL-1 beta or additional PRPr. Matrix metalloproteinase 13 gene expression and NO production were upregulated by IL-1 beta but not affected by added PRPr. Finally, PRPr reduced IL-1 beta–induced NFκB activation to control levels containing no IL-1 beta.

Conclusion: Platelet-rich plasma releasate diminished multiple inflammatory IL-1 beta–mediated effects on human osteoarthritic chondrocytes, including inhibition of NFκB activation.

Clinical Relevance: Platelet-rich plasma releasate counteracts effects of an inflammatory environment on genes regulating matrix degradation and formation in human chondrocytes. Platelet-rich plasma releasate decreases NFκB activation, a major pathway involved in the pathogenesis of OA. These results encourage further study of PRP as a treatment for OA.

Keywords: platelet-rich plasma; PRP; cartilage; chondrocyte; osteoarthritis; catabolic
platelet-derived growth factor (PDGF), and transforming growth factor–beta (TGF-beta), many of which play a pivotal role in hemostasis or tissue healing. Upon activation, platelets are triggered to release these growth factors to the injured site to stimulate various healing processes. Platelet-rich plasma can be produced by centrifugation of autologous blood, making PRP a highly concentrated, natural, and autologous treatment option for a variety of regenerative medicine fields. Several preclinical and clinical studies using PRP as a treatment for OA have been performed, reporting promising results. Unfortunately, no randomized controlled clinical trials regarding OA. Elucidating the working mechanisms of PRP in a standardized in vitro environment could provide tools to further optimize these therapies. Several studies have previously described the effects of PRP on chondrocytes in an in vitro model. These studies did not evaluate PRP primarily as a treatment option, but mainly as a culture additive in standard in vitro conditions. They describe without exception a stimulating effect of PRP on cell proliferation, although the effects on the maintenance of a chondrogenic phenotype were less concordant. However, to evaluate PRP as a therapy for OA, the in vitro environment has to simulate the in vivo situation. The joint environment in OA has shifted toward the catabolic side at the moment patients require medical care. Therefore, the emphasis may well be better directed toward understanding not only the anabolic effects, but also the effects of PRP on prevention of degeneration in an osteoarthritic environment. Interleukin (IL)-1 beta is one of the most potent inflammatory factors in osteoarthritic joints. This cytokine has been described to induce the production of destructive proteases together with the inhibition of extracellular matrix formation. Treating cells with IL-1 beta has been reported to be a useful model to reproduce the mechanisms involved in degenerative arthropathies. Interleukin-1 beta exerts its effects through a diverse spectrum of signaling cascades, including nuclear factor kappa B (NFkB) activation. Nuclear factor kappa B is normally located in an inactivated state in the cytosol bound to I kB, an inhibitory protein. Upon activation, NFkB translocates to the nucleus and acts on various regulatory genes involved in apoptosis, inflammation, and other immune responses. To determine the effects of PRP in a standardized inflammatory environment, we studied the capacity of PRP releasate (PRPr) to counteract IL-1 beta–induced effects on genes involved in matrix formation and degradation in osteoarthritic chondrocytes, including NFkB as a possible pathway through which these effects occurred.

MATERIALS AND METHODS

PRPr Preparation

Anticoagulated whole blood from 3 healthy male donors was acquired (Sanquin Blood Supply Foundation, Amsterdam, the Netherlands) after participants gave informed consent. Whole blood was further processed within 2 hours after collection. Platelet-rich plasma was prepared by means of a GPS III System (kindly provided by Biomet Nederland BV, Dordrecht, the Netherlands) according to the manufacturer’s protocol. Clotting upon addition of 22.8 mM CaCl2 1:10 (v/v) activated platelets to release their growth factors. Supernatant was collected and designated PRPr. Baseline platelet, white blood cell, and red blood cell concentrations of whole blood, PRP, and PRPr were measured on a clinical Sysmex XE-2100 automated hematoly system (Sysmex Europe, Norderstedt, Germany). Platelet-rich plasma releasate was subsequently stored in aliquots of 1.5 mL at –80°C for further experiments and growth factor analyses. Cryopreservation has been reported before to maintain the ability of PRPr to influence chondrocyte behavior. Baseline VEGF, PDGF-AA, and PDGF-AB/BB in PRPr were measured by means of a MILLIPLEX (Millpore BV, Amsterdam, the Netherlands) and TGF–beta 1 using the human TGF–B1 Immunoassay Quantikine (R&D Systems, Abingdon, United Kingdom). Two dilutions of the samples were measured for growth factor analyses. The measurements that were best in the range of the standard are reported.

Chondrocyte Culture With PRPr

Human osteoarthritic cartilage from 6 donors was obtained from patients undergoing total knee replacement surgery (after implicit consent, as approved by the local ethical committee; MEC-2004-322). Full-thickness cartilage was harvested, treated with 0.2% protease (Sigma-Aldrich, Zwijndrecht, the Netherlands) in physiologic saline solution for 90 minutes and subsequently digested overnight in standard culture medium (Dulbecco’s modified Eagle medium [DMEM] containing 10% fetal calf serum [FCS], 50 µg/mL gentamicin, and 1.5 µg/mL fungizone) supplemented with 0.15% collagenase B (Roche Diagnostics, Mannheim, Germany). After digestion, cells were washed twice with physiologic saline and the harvested cell number was determined using a hemocytometer. Alginic beads were prepared as described previously. In short, chondrocytes were suspended in 1.2% low-viscosity alginate (Kelton LV, Kelco, Surrey, United Kingdom) at a concentration of 4 million cells/mL. Beads were created by dripping the alginate/cell suspension through a 23-gauge needle into a CaCl2 solution. Chondrocytes in alginate beads were cultured in standard culture medium as described above, supplemented with 1 × 10−4 M ascorbic acid-2-phosphate (Sigma-Aldrich, St. Louis, Missouri). After chondrocytes were precultured in alginate beads for 3 weeks to allow extracellular matrix formation, beads were washed 3 times with serum-free DMEM. Subsequently, beads were placed in serum-free culture medium (DMEM containing ITS + 1:100 [v/v], 50 µg/mL gentamicin, 1.5 µg/mL fungizone, and 1 × 10−4 M ascorbic acid-2-phosphate) with or without 10 ng/mL IL-1 beta and the addition of PRPr at concentrations of 0%, 1%, and 10% (v/v). After 48 hours of culture, beads were harvested for
gene expression analyses. Forty-eight hours of culture has been described previously as a suitable time point to study the effects of IL-1 beta and various treatments on chondrocyte behavior. Additionally, beads were harvested for glycosaminoglycan (GAG) and DNA analyses and medium was harvested for nitric oxide (NO) and GAG analysis.

Gene Expression Analysis

Alginate beads were dissolved in 55 mM sodium citric acid and spun down at 350g for 8 minutes at a temperature of 4°C. Cell pellets were resuspended in RNA-BeeTM (TEL-TEST, Friendswood, Texas). RNA was extracted with chloroform and purified from the supernatant using the RNAeasy Micro Kit (Qiagen, Hilden, Germany), according to the manufacturer’s guidelines with on-column DNA digestion. Nucleic acid content was determined spectrophotometrically (NanoDrop ND1000, Isogen Life Science, Leusden, the Netherlands). Complementary DNA (cDNA) synthesis was performed using a RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany), and polymerase chain reactions (PCRs) were performed using TaqMan Universal PCR MasterMix (Applied Biosystems, Capelle a/d IJssel, the Netherlands) as described earlier. Real-time PCR primers for collagen type II alpha 1 (COL2A1), aggrecan (ACAN), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)4, ADAMTS5, and matrix metalloproteinase (MMP)13 are described earlier. Prostaglandin-endoperoxide synthase (PTGS)2 gene expression was determined using a commercial assay-on-demand set (Hs01573474.g1, Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), HPRT (hypoxanthine-guanine phosphoribosyltransferase), and beta 2-microglobulin were compared as housekeeping genes. Relative expression levels, normalized to the manufacturer’s guidelines with on-column DNA digestion. Nucleic acid content was determined spectrophotometrically (NanoDrop ND1000, Isogen Life Science, Leusden, the Netherlands). Complementary DNA (cDNA) synthesis was performed using a RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany), and polymerase chain reactions (PCRs) were performed using TaqMan Universal PCR MasterMix (Applied Biosystems, Capelle a/d IJssel, the Netherlands) as described earlier. Real-time PCR primers for collagen type II alpha 1 (COL2A1), aggrecan (ACAN), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)4, ADAMTS5, and matrix metalloproteinase (MMP)13 are described earlier. Prostaglandin-endoperoxide synthase (PTGS)2 gene expression was determined using a commercial assay-on-demand set (Hs01573474.g1, Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), HPRT (hypoxanthine-guanine phosphoribosyltransferase), and beta 2-microglobulin were compared as housekeeping genes. Relative expression levels, normalized to GAPDH as the most stably expressed of the 3 reference genes (data not shown), were calculated using the 2-\Delta\DeltaCt method.

Glycosaminoglycan and DNA Assay

Glycosaminoglycan analysis was performed by a dimethylmethylene blue (DMB) assay. Alginate beads were digested overnight at 60°C in papain buffer (250 μg/mL papain in 50 mM EDTA [ethylenediaminetetraacetic acid] and 5 mM L-cysteine). The GAG amount in the digest was quantified using a modified DMB assay, based on the original description by Farndale et al. The metachromatic reaction of GAG with DMB was monitored using a spectrophotometer, and the ratio A530:A590 was used to determine the amount of GAG present, using chondroitin sulphate C (Sigma-Aldrich) as a standard. The amount of DNA in each papain-digested sample was determined using ethidium bromide with calf thymus DNA (Sigma-Aldrich) as a standard.

Nitric Oxide Assay

Nitric oxide production was determined by quantifying its derived product, nitrite, in medium using a spectrophotometric method based upon the Griess reaction. Briefly, 100 μL of culture medium was mixed with 100 μL of Griess reagent (0.5% sulphanilamide, 0.05% naphthyl ethylenediamine dihydrochloride, 2.5% H3PO4). A serial dilution of sodium nitrite (NaNO2, Fluka, Buchs, Switzerland) was used as a standard. The absorption was measured at 540 nm.

Nuclear Factor Kappa B

To evaluate the involvement of NFκB activation in the working mechanism of PRPr, freshly isolated chondrocytes were seeded in monolayer at a density of 20 000 cells/cm². Cells were precultured in basal medium in 48-well plates until subconfluency. A preliminary study revealed 1 hour of IL-1 beta incubation to be the optimal moment to evaluate NFκB activation (data not shown), confirming a previous study by Largo et al. Cells were cultured for 1 hour in the presence or absence of IL-1 beta and PRPr at concentrations of 0%, 1%, and 10% (v/v) and subsequently fixed in formalin 4%. All conditions were simultaneously fixed per donor. Fixation was followed by incubation with NFκB-p65 Antibody (Ab-276) 1:100 (Signalway Antibody, Leusden, the Netherlands) and goat anti-rabbit AP 1:20 (Sigma-Aldrich). Freshly prepared new fuchsin was used as substrate to achieve staining. Negative controls were performed using an immunoglobulin G isotype control. Staining was performed synchronously for all conditions per donor. The percentage of positive cells was determined by 2 independent observers by scoring 3 times 100 cells/well. All separate values from both observers were used for statistical analysis.

Statistical Analysis

Experiments were performed in triplicate samples for all 3 PRPr donors on 2 separate chondrocyte donors each (6 chondrocyte donors in total). The NFκB immunohistochemistry was performed for all 3 PRPr donors on single chondrocyte donors. Statistical analysis was performed using a mixed-model analysis of variance, in which treatment was considered a fixed factor and donor a random factor. The effects of IL-1 beta and PRPr were calculated in separate models. A P value < .05 was considered statistically significant.

RESULTS

Baseline Platelet Concentration and Growth Factor Analyses

Whole blood samples contained physiologic values of platelets, white blood cells, and red blood cells for all 3 donors. Platelet-rich plasma contained on average 6.04 to 7.75 times more platelets than whole blood (Table 1). White blood cells increased in a comparable manner (5.87- to 7.24-fold increase), while red blood cell counts decreased.
After activating the PRP by clotting, platelet numbers were decreased to 0.15 to 0.83 times the baseline value of whole blood levels. Next to this, the clotting procedure decreased white blood cells to 0.48 to 1.27 times baseline and red blood cell count to 0.03 to 0.07 times baseline whole blood level. The growth factors PDGF-AA, PDGF-AB/BB, and TGF–beta 1 were abundantly present in PRPr from all 3 donors (values listed in Table 1). Vascular endothelial growth factor was found in a lower amount on average and was below detection level in 1 donor.

**PRPr Diminishes IL-1 Beta Effects on Chondrocyte Gene Expression**

The addition of the inflammatory cytokine IL-1 beta diminished expression of COL2A1 and ACAN in chondrocytes, while it increased expression of ADAMTS4, MMP13, and PTGS2 (Figure 1; *P < .03 for all genes*). Upon addition of 10% PRPr, COL2A1 gene expression increased compared with IL-1 beta–only treated samples (*P = .003*) as well as ACAN (*P = .001*), while ADAMTS4 expression was reduced (*P = .001*) as was PTGS2 (*P = .004*). The addition of 1% PRPr to our cultures revealed a trend toward normalizing COL2A1 and ADAMTS4 expression, although these results did not reach statistical significance. Matrix metalloproteinase 13 expression was not changed by PRPr, whereas ADAMTS5 was not influenced by the presence of IL-1 beta or additional PRPr.

Without the addition of IL-1 beta to our cultures, PRPr did not significantly affect COL2A1 gene expression compared with the control containing no PRPr, while ACAN showed a significant downregulation after the addition of 1% and 10% PRPr (*P ≤ .003* for both). ADAMTS4 and MMP13 were significantly upregulated by 10% PRPr (*P ≤ .002* for both), whereas ADAMTS5 was downregulated by 10% PRPr (*P = .002*). Prostaglandin-endoperoxide synthase 2 was not influenced by PRPr in the absence of IL-1 beta.

**PRPr Effects on GAG and NO Production**

Neither IL-1 beta nor simultaneous addition of PRPr showed an effect on the amount of GAG per cell in our experiments (Figure 2). Next to this, no effects were seen on GAG release in the medium, DNA content per bead, or total GAG per bead (data not shown). Moreover, PRPr did not alter any of these parameters in the absence of IL-1 beta (data not shown). We also determined the effect of PRPr on NO production in IL-1 beta–treated chondrocyte cultures. Platelet-rich plasma releasate was unable to counteract the IL-1 beta–induced production of this inflammatory mediator (Figure 3). In the absence of IL-1 beta, PRPr alone did not induce production of NO by osteoarthritic chondrocytes (data not shown).

**PRPr Reduces IL-1 Beta–Induced NFκB Activation**

To determine a possible mechanism through which PRPr exerts its effects, we studied the effect of PRPr on NFκB activation using immunohistochemistry. This revealed NFκB activation in our IL-1 beta–treated chondrocytes, which was reduced by PRPr (Figure 3A-C). Manually scoring these cells showed IL-1 beta to cause a marked increase in NFκB-activated chondrocytes (Figure 3D; *P = .001*). This activation was downregulated by PRPr (*P < .001* for both doses) in a dose-dependent manner. The highest concentration of PRPr (10%) reduced the amount of NFκB-activated chondrocytes back to control levels.

**DISCUSSION**

In this study, we tested our hypothesis that PRPr has anti-inflammatory properties and influences gene expression of matrix-forming and matrix-degrading proteins in an OA-mimicking environment. The osteoarthritic and
an inflammatory environment was created through addition of IL-1 beta, one of the key players in OA pathogenesis, to chondrocytes in culture. Exposure of chondrocytes to the inflammatory cytokine IL-1 beta resulted in marked changes in the expression of genes involved in matrix formation and degradation as well as inflammation, many of which were reduced by the addition of PRP. Platelet-rich plasma releasate ameliorated the IL-1 beta–induced changes on chondrocyte gene expression of COL2A1, ACAN, ADAMTS4, and PTGS2. The inhibition of NFκB activation was found to be a possible mechanism through which PRP exerted these effects.

Various research groups have studied the use of PRP mainly as a culture supplement for chondrocytes. A consistent finding in their reports is that PRP increases cell proliferation. However, some describe an increased gene expression or synthesis of COL2A1 and ACAN upon PRP addition, while others mention PRP to decrease these parameters. We consider these contradicting reports and our own results using PRP in the absence of IL-1 beta to hinder a clear statement regarding the use of PRP in OA treatment.
of PRP as a culture supplement for chondrocytes. A major difference between these previous reports and the focus of our current study is the fact that we did not evaluate PRP as a culture additive, but aimed at establishing the potential of PRP as a possible treatment for OA. For this application, PRP should preferably restore the anabolic-catabolic imbalance found in OA joints. By applying PRP to osteoarthritic chondrocytes in a standardized IL-1 beta–mediated

Figure 2. Influence of platelet-rich plasma releasate (PRPr) on glycosaminoglycan (GAG)/DNA and nitric oxide (NO) in the presence of interleukin (IL)-1 beta. No effects on GAG per cell were found by IL-1 beta or additional PRPr. Interleukin-1 beta increased NO release by chondrocytes; additional PRPr did not alter this. Data are shown relative to control as means ± standard deviations for 6 experiments. *Indicates P < .05 compared with control without IL-1 beta.

Figure 3. Effect of platelet-rich plasma releasate (PRPr) on interleukin (IL)-1 beta–induced nuclear factor kappa B (NFκB) activation. Nuclear factor kappa B immunohistochemistry showing IL-1 beta–treated chondrocytes in the absence of PRPr (A) and the presence of 10% PRPr (B). Panel C represents immunoglobulin G (IgG) control. Dotted arrows in panel A resemble negative cells, whereas solid arrows in panel B indicate NFκB activated cells. D, interleukin-1 beta induced NFκB activation, which was dose-dependently reduced by PRPr. Data are presented as means ± standard deviations for 3 experiments. Magnification (A-C) ×200. *Indicates P < .05 compared with control without IL-1 beta; #indicates P < .05 versus control with IL-1 beta.
inflammatory and catabolic environment, our results indicated consistent anti-inflammatory effects of PRP.

Platelet-rich plasma inhibited the translocation of NFκB to the nucleus. Nuclear factor kappa B is present as an inactive, inhibitor-bound complex in almost all mammalian cells and gets translocated into the nucleus upon activation. It regulates more than 150 genes, including those involved in inflammation and other immune responses. In chondrocytes, NFκB has been reported to inhibit COL2A1 gene expression and to regulate MMP1, MMP3, MMP13, IL-8, and MCP-1 (monocyte chemotactic protein 1) expression. Several pharmacologic agents act as NFκB inhibitors, including nonsteroidal anti-inflammatory drugs, glucocorticoids, and proteasome inhibitors. Nuclear factor kappa B inhibition by PRP has been recently reported in a human immortalized chondrocyte cell line. We were able to confirm the latter result using primary human osteoarthritic chondrocytes, thereby providing a link toward clinical application.

Nitric oxide production is increased in OA joints, and has been described to inhibit collagen and GAG synthesis while inducing chondrocyte apoptosis and the production of metalloproteinases. Vuolteenaho et al previously reported that both TGF-beta and an NFκB inhibitor decreased IL-1 beta–induced NO production by immortalized murine chondrocytes. Interleukin-1 beta induced an evident increase in NFκB activation and NO production in our experiments, but PRPr only counteracted the first effect. Transforming growth factor–beta was abundantly present in our PRPr, and the amount of TGF-beta in the condition where we used 10% PRPr exceeded that used by Vuolteenaho et al. The different origin of our cells or the heterogeneity and multitude of growth factors present in PRP, affecting many regulatory pathways, could be possible explanations for the fact that we did not observe an inhibitory effect of PRPr on NO production. Although PRP could be a promising autologous treatment option with many applications, this heterogeneity and multitude of growth factors present in PRP substantially limits the ability to understand and investigate the effects of PRP. This could also explain the different PRP-mediated effects we observed in an environment with versus without IL-1 beta.

A limitation of our study is the use of a short-term in vitro model to study PRP as a possible OA treatment. In our model, we did not detect catabolic effects of IL-1 beta on GAG content at a protein level, although we observed clear downregulation of ACAN gene expression in PRP, affecting many regulatory pathways, could be possible explanations for the fact that we did not observe an inhibitory effect of PRP on NO production. Although PRP could be a promising autologous treatment option with many applications, this heterogeneity and multitude of growth factors present in PRP substantially limits the ability to understand and investigate the effects of PRP. This could also explain the different PRP-mediated effects we observed in an environment with versus without IL-1 beta.

ACKNOWLEDGMENT

We acknowledge Stefan Clockaerts for his help in scoring NFκB immunohistochemistry.

REFERENCES


For reprints and permission queries, please visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav